Barclays PLC lifted its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) by 7,615.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 90,429 shares of the company's stock after buying an additional 89,257 shares during the quarter. Barclays PLC owned about 0.12% of Day One Biopharmaceuticals worth $1,812,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the stock. ExodusPoint Capital Management LP purchased a new stake in Day One Biopharmaceuticals in the 2nd quarter valued at $412,000. Goldman Sachs Group Inc. raised its position in Day One Biopharmaceuticals by 5,969.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,894,537 shares of the company's stock valued at $33,912,000 after purchasing an additional 1,863,325 shares during the last quarter. Macquarie Group Ltd. purchased a new stake in Day One Biopharmaceuticals in the 2nd quarter valued at $1,969,000. Woodline Partners LP purchased a new stake in Day One Biopharmaceuticals in the 2nd quarter valued at $2,688,000. Finally, Price T Rowe Associates Inc. MD raised its position in Day One Biopharmaceuticals by 28.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,041,344 shares of the company's stock valued at $36,540,000 after purchasing an additional 455,603 shares during the last quarter. Hedge funds and other institutional investors own 86.08% of the company's stock.
Get Day One Biopharmaceuticals alerts:Insider Activity at Day One Biopharmaceuticals
In related news, CEO Jeremy Bender sold 1,513 shares of the stock in a transaction dated Wednesday, November 16th. The shares were sold at an average price of $21.46, for a total value of $32,468.98. Following the sale, the chief executive officer now directly owns 1,217,424 shares of the company's stock, valued at approximately $26,125,919.04. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the firm's stock in a transaction dated Tuesday, January 10th. The shares were sold at an average price of $22.86, for a total transaction of $228,600.00. Following the sale, the insider now directly owns 1,250,148 shares of the company's stock, valued at approximately $28,578,383.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jeremy Bender sold 1,513 shares of the business's stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $21.46, for a total transaction of $32,468.98. Following the completion of the transaction, the chief executive officer now directly owns 1,217,424 shares of the company's stock, valued at approximately $26,125,919.04. The disclosure for this sale can be found here. In the last three months, insiders have sold 124,178 shares of company stock valued at $2,638,412. Insiders own 8.70% of the company's stock.
Analysts Set New Price Targets
Several research firms recently commented on DAWN. Piper Sandler upped their price target on shares of Day One Biopharmaceuticals from $40.00 to $45.00 and gave the company an "overweight" rating in a research report on Sunday, January 8th. Oppenheimer began coverage on shares of Day One Biopharmaceuticals in a research note on Thursday. They issued a "market perform" rating on the stock. The Goldman Sachs Group boosted their price objective on shares of Day One Biopharmaceuticals from $45.00 to $62.00 and gave the company a "buy" rating in a research note on Monday, January 9th. Bank of America began coverage on shares of Day One Biopharmaceuticals in a research note on Thursday, December 1st. They issued a "buy" rating and a $34.00 price objective on the stock. Finally, Needham & Company LLC began coverage on shares of Day One Biopharmaceuticals in a research note on Wednesday, December 14th. They issued a "buy" rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $43.50.Day One Biopharmaceuticals Stock Down 2.9 %
NASDAQ:DAWN opened at $21.11 on Friday. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $5.44 and a fifty-two week high of $28.35. The firm's fifty day simple moving average is $21.35 and its 200-day simple moving average is $21.23.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) last posted its quarterly earnings results on Monday, November 7th. The company reported ($0.53) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.53). As a group, analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.18 EPS for the current year.
Day One Biopharmaceuticals Profile
(Get Rating)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
Further Reading
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Want to see what other hedge funds are holding DAWN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating).
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.